AIMS: Diabetes mellitus, chronic obstructive pulmonary disease, and chronic kidney disease are prevalent in patients with heart failure with reduced ejection fraction (HFrEF). We have analysed the impact of co-morbidities on quality of life (QoL) and outcome. METHODS AND RESULTS: A total of 397 patients (58.8 ± 11.0 years, 73.6% with New York Heart Association functional class ≥3) with stable advanced HFrEF were followed for a median of 1106 (inter-quartile range 379-2606) days, and 68% of patients (270 patients) experienced an adverse outcome (death, urgent heart transplantation, and implantation of mechanical circulatory support). Chronic obstructive pulmonary disease was present in 16.4%, diabetes mellitus in 44.3%, and chronic kidney disease in 34.5% of patients; 33.5% of patients had none, 40.0% had one, 21.9% had two, and 3.8% of patient had three co-morbidities. Patients with more co-morbidities reported similar QoL (assessed by Minnesota Living with Heart Failure Questionnaire, 45.46 ± 22.21/49.07 ± 21.69/47.52 ± 23.54/46.77 ± 23.60 in patients with zero to three co-morbidities, P for trend = 0.51). Multivariable regression analysis revealed that furosemide daily dose, systolic blood pressure, New York Heart Association functional class, and body mass index, but not the number of co-morbidities, were significantly (P < 0.05) associated with QoL. Increasing co-morbidity burden was associated with worse survival (P < 0.0001), lower degree of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker treatment (P = 0.001), and increasing levels of BNP (mean of 685, 912, 1053, and 985 ng/L for patients with zero to three co-morbidities, P for trend = 0.008) and cardiac troponin (sm-cTnI, P for trend = 0.0496), which remained significant (P < 0.05) after the adjustment for left ventricular ejection fraction, left ventricular end-diastolic diameter, right ventricular dysfunction grade, body mass index, and estimated glomerular filtration rate. CONCLUSIONS: In stable advanced HFrEF patients, co-morbidities are not associated with impaired QoL, but negatively affect the prognosis both directly and indirectly through lower level of HF pharmacotherapy and increased myocardial stress and injury.

3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Cardiology Institute for Clinical and Experimental Medicine IKEM Vídeňská 1958 9 Prague 4 140 21 Czech Republic

Department of Internal Medicine 1st Faculty of Medicine Charles University and Military University Hospital Prague Prague Czech Republic

Department of Laboratory Methods Institute for Clinical and Experimental Medicine IKEM Prague Czech Republic

Zobrazit více v PubMed

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population‐based study of 4 million individuals. Lancet (London, England) 2018; 391: 572–580. PubMed PMC

Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Non‐cardiovascular comorbidity, severity and prognosis in non‐selected heart failure populations: a systematic review and meta‐analysis. Int J Cardiol 2015; 196: 98–106. PubMed PMC

Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long‐term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101: 353–358. PubMed

Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non‐ischaemic aetiology. Diab Vasc Dis Res 2013; 10: 330–336. PubMed

Lofman I, Szummer K, Hagerman I, Dahlstrom U, Lund LH, Jernberg T. Prevalence and prognostic impact of kidney disease on heart failure patients. Open heart 2016; 3: e000324. PubMed PMC

Jonsson A, Hallberg AC, Edner M, Lund LH, Dahlstrom U. A comprehensive assessment of the association between anemia, clinical covariates and outcomes in a population‐wide heart failure registry. Int J Cardiol 2016; 211: 124–131. PubMed

van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, Maggioni AP, Voors AA. Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103–111. PubMed

Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42: 1226–1233. PubMed

Rorth R, Jhund PS, Kristensen SL, Desai AS, Kober L, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail 2019; 21: 40–49. PubMed PMC

Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y, Yamauchi H, Iwaya S, Owada T, Miyata M, Abe S, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh S, Takeishi Y. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014; 64: 256–264. PubMed

Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test‐induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009; 30: 162–169. PubMed PMC

Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two‐dimensional echocardiography. Am Heart J 1984; 107: 526–531. PubMed

Meluzín J, Spinarová L, Bakala J, Toman J, Krejcí J, Hude P, Kára T, Soucek M. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non‐invasive method of evaluating right ventricular systolic function. Eur Heart J 2001; 22: 340–348. PubMed

Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2660–2667. PubMed

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108. PubMed

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S266. PubMed

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa‐Uva M, Valensi P, Wheeler DC. 2019 ESC guidelines on diabetes, pre‐diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323. PubMed

Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G. Reframing the association and significance of co‐morbidities in heart failure. Eur J Heart Fail 2016; 18: 744–758. PubMed

Chopra VK, Anker SD. Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Failure 2020; 7: 2007–2011. PubMed PMC

Bourguignon S, Faller M, Champs FO, Moutier H, Levesque K, Caranhac G, Cohen‐Solal A. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Failure 2019; 6: 559–569. PubMed PMC

Nguyen M, Rumjaun S, Lowe‐Jones R, Ster IC, Rosano G, Anderson L, Banerjee D. Management and outcomes of heart failure patients with CKD: experience from an inter‐disciplinary clinic. ESC Heart Failure 2020; 7: 3225–3230. PubMed PMC

Frohlich H, Nelges C, Tager T, Schwenger V, Cebola R, Schnorbach J, Goode KM, Kazmi S, Katus HA, Cleland JG, Clark AL, Frankenstein L. Long‐term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J 2016; 178: 28–36. PubMed

Gurwitz JH, Magid DJ, Smith DH, Tabada GH, Sung SH, Allen LA, McManus DD, Goldberg RJ, Tisminetzky M, Go AS. Treatment effectiveness in heart failure with comorbidity: lung disease and kidney disease. J Am Geriatr Soc 2017; 65: 2610–2618. PubMed PMC

Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC heart Failure 2018; 5: 257–266. PubMed PMC

Alonso N, Lupón J, Barallat J, de Antonio M, Domingo M, Zamora E, Moliner P, Galán A, Santesmases J, Pastor C, Mauricio D, Bayes‐Genis A. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc Diabetol 2016; 15: 151. PubMed PMC

Savoj J, Becerra B, Kim JK, Fusaro M, Gallieni M, Lombardo D, Lau WL. Utility of cardiac biomarkers in the setting of kidney disease. Nephron 2019; 141: 227–235. PubMed

Ooi DS, Isotalo PA, Veinot JP. Correlation of antemortem serum creatine kinase, creatine kinase‐MB, troponin I, and troponin T with cardiac pathology. Clin Chem 2000; 46: 338–344. PubMed

Mishra RK, Li Y, DeFilippi C, Fischer MJ, Yang W, Keane M, Chen J, He J, Kallem R, Horwitz EJ, Rafey M, Raj DS, Go AS, Shlipak MG. Association of cardiac troponin T with left ventricular structure and function in CKD. Am J Kidney Dis 2013; 61: 701–709. PubMed PMC

Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Diamond GA, Fesmire FM, Geraci SA, Gersh BJ, Larsen GC, Kaul S, McKay CR, Philippides GJ, Weintraub WS. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012; 60: 2427–2463. PubMed

Sabit R, Bolton CE, Fraser AG, Edwards JM, Edwards PH, Ionescu AA, Cockcroft JR, Shale DJ. Sub‐clinical left and right ventricular dysfunction in patients with COPD. Respir Med 2010; 104: 1171–1178. PubMed

Nakai H, Takeuchi M, Nishikage T, Lang RM, Otsuji Y. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two‐dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr 2009; 10: 926–932. PubMed

Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2016; 18: 103–112. PubMed PMC

Yan I, Börschel CS, Neumann JT, Sprünker NA, Makarova N, Kontto J, Kuulasmaa K, Salomaa V, Magnussen C, Iacoviello L, Di Castelnuovo A, Costanzo S, Linneberg A, Söderberg S, Zeller T, Ojeda‐Echevarria FM, Blankenberg S, Westermann D. High‐sensitivity cardiac troponin I levels and prediction of heart failure: results from the BiomarCaRE Consortium. JACC Heart Failure 2020; 8: 401–411. PubMed

Januzzi JL Jr, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston‐Miller N, Mark DB, Piña IL, Passmore G, Whellan DJ, Cooper LS, Leifer ES, Desvigne‐Nickens P, Felker GM, O'Connor CM. Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction. J Am Coll Cardiol 2019; 74: 1205–1217. PubMed PMC

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med 2019; 381: 1995–2008. PubMed

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner‐La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F. Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl J Med 2020; 383: 1413–1424. PubMed

Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure

Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)